[Effects of bronchial artery infusion (B-AI) with single use of MMC after intravenous peplomycin (PEP) administration in lung cancer].
Effects of BAI therapy on 86 cases of lung cancer were evaluated in three groups: single-use of MMC group after intravenous PEP administration (PEP (iv).MMC group), PEP and MMC combination use group (PEP + MMC group) and single use of MMC group. Tumor regression rate determined by chest X-ray film 2 or 3 weeks after BAI was highest in the PEP (iv).MMC group followed by the PEP + MMC and MMC group. Cavity formation was more typical in the group treated with PEP + MMC. Histopathological effects were best for the PEP + MMC group followed by those of the PEP (iv).MMC and MMC group. As for side effects, pulmonary fibrosis and necrotizing bronchitis were noted in 8% of the PEP + MMC group, but side effects in the other two groups were mild. In conclusion single use of MMC after intravenous PEP administration was found to be the best way to give BAI in these three groups.
Yokoyama
K
K
Takashima
T
T
Nozaki
M
M
Kurokawa
A
A
Matsumoto
K
K
D000230:Adenocarcinoma / Q000188:drug therapy; D001761:Bleomycin / Q000008:administration & dosage*; D001981:Bronchial Arteries; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D006801:Humans; D007261:Infusions, Intra-Arterial; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage*; D017663:Peplomycin
D008937:Mitomycins; D001761:Bleomycin; D016685:Mitomycin; D017663:Peplomycin